Clinical significance of minimal residual disease in patients with Ph-negative precursor B-acute lymphoblastic leukemia
10.3760/cma.j.issn.0253-2727.2018.09.004
- VernacularTitle: 微小残留病在Ph染色体阴性急性B淋巴细胞白血病中的预后意义
- Author:
Kaiqi LIU
1
;
Hui WEI
;
Dong LIN
;
Ying WANG
;
Chunlin ZHOU
;
Bingcheng LIU
;
Wei LI
;
Xingli ZHAO
;
Yan LI
;
Huijun WANG
;
Chengwen LI
;
Qinghua LI
;
Benfa GONG
;
Yuntao LIU
;
Xiaoyuan GONG
;
Yingchang MI
;
Jianxiang WANG
Author Information
1. Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
- Publication Type:Journal Article
- Keywords:
Minimal residual disease;
Flow Cytometry;
Leukemia, lymphoblastic;
Prognosis
- From:
Chinese Journal of Hematology
2018;39(9):724-728
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the predictive value of minimal residual disease (MRD) level in Ph-negative precursor B-acute lymphoblastic leukemia (ALL) patients.
Methods:De novo 193 Ph-negative B-ALL patients from Sep 2010 to Nov 2017 were involved in the study. The patients' MRD evaluation which can be performed by multiparametric flow cytometry (MFC) after 1 month, 3-month, 6-month treatment. Relapse free survival (RFS) and overall survival (OS) were compared in patients with different MRD level.
Results:The median follow-up was 22 months. All patients was evaluated at 497 MRD level. Patients who reach the good MRD level at 1 month (<0.1% or ≥0.1%), 3-month (negative or positive), 6-month (negative or positive) had a significantly higher probability of estimated RFS (74.5% vs 29.9%; 75.6% vs 29.7%; 74.6% vs 11.6%) and of estimated OS (67.5% vs 30.3%; 71.6% vs 27.8%; 74.0% vs 15.7%). Patients who reach the MRD negative at all 3 times had a significantly higher probability of estimated RFS (80.5% vs 30.5%) and better estimated OS (77.1% vs 29.4%) compared to patients with at least MRD failure in one time (P<0.001). Multivariable analysis showed MRD level at 3-month was an independent prognostic factor for DFS and OS.
Conclusion:MRD is an important prognosis factor for Ph-negative B- ALL patients.
